ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days
in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group
II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to
reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks after
initiation of treatment.